Moderna COVID-19 Shot Lowers Risk Of Infection, Hospitalization Compared To Pfizer's
Moderna COVID-19 Shot Lowers Risk Of Infection, Hospitalization Compared To Pfizer's
A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received $Pfizer(PFE.US)$ COVID-19 vaccine, $Moderna(MRNA.US)$ vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations.
退伍军人事务部(VA)资助的一项新的现实世界研究显示，与那些接受$辉瑞(PFE.US)$新冠肺炎疫苗，$Moderna(MRNA.US)$接种疫苗的人感染SARS-CoV-2和相关住院的风险显著降低。
Lower risk was observed across all age groups, comorbidity-burden categories, and race.
Authors of the study, published as a pre-print last week, noted differences between Moderna's mRNA-1273 vaccine and Pfizer's BNT162b2 "in risk of infection or hospitalization were progressively greater when the follow-up period was longer."
The study evaluated over 900,000 vaccine recipients, followed for a mean of 192 days, during which there were almost 17,000 infections, more than 3,500 hospitalizations, and 381 deaths.
While fewer patients who received Moderna's vaccine died than Pfizer (168 versus 213), the researchers said this difference was not statistically significant.
Price Action: PFE stock is up 0.17% at $56.32, MRNA stock is down 4.63% at $222.88 during the market session on the last check Tuesday.
在所有年龄组、共病负担类别和种族中都观察到较低的风险。
这项研究的作者上周发表了一份预印本，指出Moderna的mrna-1273mRNA-1273疫苗和辉瑞的bnt162b2之间的不同之处在于，“随着随访期的延长，感染或住院的风险逐渐增大。”
这项研究评估了超过90万名疫苗接受者，平均持续192天，在此期间有近1.7万人感染，3500多人住院，381人死亡。
虽然接种Moderna疫苗的患者死亡人数比辉瑞少(168人比213人)，但研究人员表示，这一差异在统计学上并不显著。
价格行动：周二尾盘，PFE股票上涨0.17%，至56.32美元，mRNA股票下跌4.63%，至222.88美元。